Biological Aging, Healthy Aging, Longevity
Conditions
Keywords
Epigenetic age, Phenotypic age, Autologous conditioned media, Longevity protocol, Supplements, Lifestyle
Brief summary
This pilot study evaluated a multi-modal longevity protocol combining lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media derived from peripheral blood-derived pro-regenerative cells (APRC-CM). Fourteen healthy adult participants completed a 17-week programme including baseline and post-intervention biomarker assessments. The primary objective was to characterise changes in biological age using DNA methylation-based epigenetic clocks, PhenoAge and other physiological and biochemical markers.
Detailed description
This exploratory study investigated the biological effects of a structured, multi-modal longevity programme that included lifestyle optimisation (nutrition, exercise, sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells cultured ex vivo to produce a pro-regenerative secretome containing soluble factors and extracellular vesicles. Participants underwent biomarker assessments at baseline and at week 17. Outcomes included measurements of epigenetic biological age, phenotypic age, inflammatory markers, metabolic markers, and other laboratory and physiological variables. The study was conducted in healthy adults and designed as a minimal-risk physiological investigation.
Interventions
BEHAVIORALMulti-Modal Longevity Protocol
The intervention consisted of a structured, multi-modal longevity program that included lifestyle optimization (nutrition, physical activity, and sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells and administered as part of a physiologic, minimal-risk exploratory protocol.
Sponsors
xLongevity
Wellbeing International Foundation
BlueBird Age Reversal SA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Single-arm exploratory study in which all participants received the same multi-modal longevity protocol, including lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). No comparator group was included.
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 45 years or older * Generally good overall health as assessed by the study team * Able and willing to provide written informed consent * Willing to participate in all components of the study protocol, including lifestyle optimisation, nutritional supplementation, blood collection, and scheduled follow-up visits * Able to comply with study procedures for the duration of the intervention and assessments
Exclusion criteria
* Presence of a major medical condition that, in the opinion of the investigators, could affect participation or safety * Any condition requiring hospitalization or emergency medical intervention within the past 12 months * Receipt of anti-aging or longevity treatments within the past six months (e.g., intravenous therapies, regenerative or cellular treatments, structured age-reversal programmes) * Active infectious disease at enrolment * Pregnancy or breastfeeding * Use of systemic immunomodulatory, cytotoxic, or investigational treatments in the prior 3 months * Any condition or circumstance that, in the judgement of the investigators, may interfere with study participation or data integrity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Epigenetic Biological Age | Baseline and Week 17 | Biological age calculated from DNA methylation profiles using validated epigenetic clock algorithms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Phenotypic Age | Baseline and Week 17 | Phenotypic age calculated from clinical biomarkers using published phenotypic age algorithms. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events | From baseline to Week 17 | Monitoring of any self-reported or observed adverse events throughout the study period. Events were recorded and assessed descriptively. |
Countries
United Kingdom
Outcome results
None listed